Yixining (Ebronucimab Injection) – Hypercholesterolemia | HongKong DengYue Medicine

Ebronucimab Injection Application Scope

• Indication:

  • Primary hypercholesterolemia

  • Mixed hyperlipidemia

  • Heterozygous familial hypercholesterolemia (HeFH)

• Therapeutic Area:

  • Cardiovascular / Lipid-lowering therapy

• Mechanism:

  • Fully human monoclonal antibody against PCSK9, lowering LDL-C levels.

Ebronucimab Injection Characteristics

• Ingredients: Each prefilled syringe contains 150 mg of ebronucimab.

• Properties:​ A fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

• Packaging Specification:​ 150 mg/1 mL × 1 prefilled syringe/box

• Storage:​ Store in a refrigerator at 2–8°C (36–46°F). Do not freeze. Protect from light.

• Expiry Date: As indicated on the packaging.

• Executive Standard: ​Chinese Pharmacopoeia and NMPA regulations.

• Approval Number: NMPA Approval No. [Specific number not provided in available sources].

• Date of Revision: [Specific date not provided in available sources].

• Manufacturer: Akeso Biopharma Co., Ltd.

Guidelines for the Use of Yixining

• Dosage and Administration:

  • Recommended Dose: 150 mg administered subcutaneously.

  • Administration: Administer every 2 weeks for the first 3 doses, then every 4 weeks thereafter.

  • Missed Dose:​ If a dose is missed, administer as soon as possible and resume the regular dosing schedule.

• Adverse Reactions:

  • Common Adverse Reactions: Injection site reactions, nasopharyngitis, upper respiratory tract infections.

  • Serious Adverse Reactions: Hypersensitivity reactions, including anaphylaxis.

    ​

• Contraindications: Hypersensitivity to ebronucimab or any component of the formulation.

• Precautions:

  • Monitor for signs of hypersensitivity during and after administration.

Ebronucimab Injection Interactions

• Drug Interactions:
  No significant drug interactions have been identified.

• Food Interactions:
  No known food interactions.

• Laboratory Test Interactions:
  None reported.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.